Free Trial

Denali Therapeutics (DNLI) Competitors

Denali Therapeutics logo
$15.35 +0.35 (+2.33%)
Closing price 04:00 PM Eastern
Extended Trading
$15.38 +0.03 (+0.20%)
As of 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DNLI vs. BEAM, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVL

Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Denali Therapeutics vs. Its Competitors

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Denali Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for Denali Therapeutics and 7 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.60 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$330.53M6.75-$422.77M-$2.67-5.75
Beam Therapeutics$63.52M34.88-$376.74M-$4.61-4.78

Denali Therapeutics presently has a consensus target price of $33.71, indicating a potential upside of 119.64%. Beam Therapeutics has a consensus target price of $48.75, indicating a potential upside of 121.29%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
0 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.06
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00

Denali Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Denali Therapeutics' return on equity of -35.90% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Denali TherapeuticsN/A -35.90% -32.41%
Beam Therapeutics -609.24%-44.24%-30.97%

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Denali Therapeutics beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNLI vs. The Competition

MetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.18B$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-5.758.0519.5820.23
Price / Sales6.75296.11442.27127.79
Price / CashN/A42.7337.5058.41
Price / Book1.807.748.085.60
Net Income-$422.77M-$54.96M$3.16B$248.43M
7 Day Performance4.46%6.04%3.77%5.15%
1 Month Performance0.59%4.47%3.90%7.62%
1 Year Performance-29.10%6.12%34.22%21.56%

Denali Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNLI
Denali Therapeutics
4.7159 of 5 stars
$15.35
+2.3%
$33.71
+119.6%
-28.4%$2.18B$330.53M-5.75430News Coverage
Analyst Revision
BEAM
Beam Therapeutics
2.6909 of 5 stars
$19.18
-4.1%
$48.75
+154.2%
-10.0%$1.93B$63.52M-4.16510News Coverage
Gap Up
BBIO
BridgeBio Pharma
4.6884 of 5 stars
$43.50
-1.1%
$58.85
+35.3%
+78.9%$8.26B$221.90M-12.32400Analyst Upgrade
VRNA
Verona Pharma PLC American Depositary Share
1.7228 of 5 stars
$91.20
-0.4%
$107.36
+17.7%
+514.8%$7.76B$42.28M-45.6030Trending News
Analyst Forecast
ROIV
Roivant Sciences
2.1984 of 5 stars
$10.74
-2.3%
$17.50
+62.9%
+3.6%$7.30B$29.05M-42.96860News Coverage
Analyst Forecast
ELAN
Elanco Animal Health
2.391 of 5 stars
$14.48
-1.1%
$15.33
+5.9%
+9.1%$7.19B$4.44B19.579,000
RVMD
Revolution Medicines
4.5616 of 5 stars
$36.67
-3.2%
$67.58
+84.3%
-12.3%$6.83B$11.58M-9.17250News Coverage
LEGN
Legend Biotech
2.9297 of 5 stars
$35.87
+0.6%
$72.60
+102.4%
-15.5%$6.59B$728.30M-60.802,609Positive News
Analyst Forecast
GRFS
Grifols
3.6388 of 5 stars
$8.87
-2.3%
$10.30
+16.1%
+12.2%$6.10B$7.81B7.5823,822Analyst Upgrade
Gap Up
TGTX
TG Therapeutics
4.021 of 5 stars
$35.98
-2.0%
$40.80
+13.4%
+90.5%$5.71B$329M149.92290Positive News
Analyst Forecast
NUVL
Nuvalent
3.8058 of 5 stars
$77.93
-3.2%
$119.60
+53.5%
+10.7%$5.60BN/A-17.7540

Related Companies and Tools


This page (NASDAQ:DNLI) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners